85 results on '"Muda AO"'
Search Results
2. Receptor Activator of NF-kappa B (RANK) Expression in Primary Tumors Associates with Bone Metastasis Occurrence in Breast Cancer Patients
- Author
-
Santini, D, Schiavon, Gaia, Vincenzi, B, Gaeta, L, Pantano, F, Russo, AP, Ortega, C, Porta, C, Galluzzo, S, Armento, G, La Verde, N, Caroti, C, Treilleux, I, Ruggiero, Alessandro, Perrone, G, Addeo, R, Clezardin, P, Muda, AO, Tonini, G, Santini, D, Schiavon, Gaia, Vincenzi, B, Gaeta, L, Pantano, F, Russo, AP, Ortega, C, Porta, C, Galluzzo, S, Armento, G, La Verde, N, Caroti, C, Treilleux, I, Ruggiero, Alessandro, Perrone, G, Addeo, R, Clezardin, P, Muda, AO, and Tonini, G
- Abstract
Background: Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG. Materials and Methods: We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and survival. Results: Microarray analysis showed that lower RANK and high OPG mRNA levels correlate with longer overall survival (P = 0.0078 and 0.0335, respectively) and disease-free survival (P = 0.059 and 0.0402, respectively). Immunohistochemical analysis of RANK showed a positive correlation with the development of bone metastases (P = 0.023) and a shorter skeletal disease-free survival (SDFS, P = 0.037). Specifically, univariate analysis of survival showed that "RANK-negative'' and "RANK-positive'' patients had a SDFS of 105.7 months (95% CI: 73.9-124.4) and 58.9 months (95% CI: 34.7-68.5), respectively. RANK protein expression was also associated with accelerated bone metastasis formation in a multivariate analysis (P = 0.029). Conclusions: This is the first demonstration of the role of RANK expression in primary tumors as a predictive marker of bone metastasis occurrence and SDFS in a large population of breast cancer patients.
- Published
- 2011
3. CHONDROBLASTOMA OF THE RIB PRESENTING AS AN INTRATHORACIC MASS - REPORT OF A CASE WITH FINE NEEDLE ASPIRATION BIOPSY, IMMUNOCYTOCHEMISTRY AND ELECTRON-MICROSCOPY
- Author
-
Ascoli, V., Facciolo, F., Muda, Ao, Martelli, M., and Nardi, F.
- Published
- 1992
4. Indeterminate cell histiocytosis: a rare histiocytic disorder
- Author
-
Manente, L, Cotellessa, C, Schmitt, I, Peris, Ketty, Torlone, G, Muda, Ao, Romano, Mc, Chementi, S., Peris, Ketty (ORCID:0000-0002-5237-0463), Manente, L, Cotellessa, C, Schmitt, I, Peris, Ketty, Torlone, G, Muda, Ao, Romano, Mc, Chementi, S., and Peris, Ketty (ORCID:0000-0002-5237-0463)
- Abstract
A 64-year-old woman, otherwise healthy, presented with multiple reddish-brown, slightly yellowish papules on the face and neck, which had developed 3 years earlier. The lesions were painless and nonpruritic and varied in diameter from 1 to 5 mm. Histological and immunohistochemical examination of cutaneous biopsies revealed a diffuse dermal infiltrate composed mainly of histiocytes which expressed both Langerhans cell as well as monocytic/macrophages cell marker characteristics. Electron microscopic studies revealed no Birbeck granules within the cytoplasm of the neoplastic cells, leading to a diagnosis of indeterminate cell histiocytosis. Indeterminate cell histiocytosis is a very rare disease characterized by the proliferation of indeterminate histiocytes which morphologically and immunophenotypically resemble Langerhans cells but lack Birbeck granules.
- Published
- 1997
5. Expression of TGF-β receptors type I and II in human glomerulonephritis.
- Author
-
Muda, AO, Feriozzi, S, Rahimi, S, and Faraggiana, T
- Abstract
Background.Transforming growth factor-β (TGF-β) is a multipotent cytokine involved in the turnover of the extracellular matrix. Signal transduction of TGF-β is regulated via at least five different surface receptors; most of the effects, however, are mediated through the interaction of receptors type I and II (RI and RII). We investigated the glomerular expression of TGF-β and its receptors RI and RII in human glomerulonephritis. [ABSTRACT FROM PUBLISHER]
- Published
- 1998
- Full Text
- View/download PDF
6. Transforming growth factor-beta enhances adhesion of melanoma cells to the endothelium in vitro
- Author
-
Teti, ANNA MARIA, Degiorgi, A, Spinella, Mt, Migliaccio, S, Canipari, R, Muda, Ao, and Faraggiana, T.
7. Predictive factors of outcome after liver transplantation in patients with liver cirrhosis and hepatocellular carcinoma
- Author
-
Merli, Manuela, Nicolini, G, Gentile, F, Indrio, G, Iappelli, Massimo, Rossi, Massimo, Berloco, Pasquale Bartolomeo, DI TONDO, Ugo, Muda, Ao, GINANNI CORRADINI, Stefano, Nudo, Francesco, and Attili, Adolfo Francesco
8. Immunophenotype characterization of gastric mucosa lymphocytes in common variable immunodeficiency gastritis
- Author
-
Rahimi, S., Rinaldi, V., Zullo, A., Luzi, G., Mattiacci, G., Muda, Ao, and Faraggiana, T.
9. PML down-regulation in soft tissue sarcomas
- Author
-
Sabrina Rossi, Andrea Onetti Muda, Marianna Silletta, Nicola Gebbia, Federica Grosso, Giuseppe Perrone, Daniele Santini, A.M. Frezza, Angelo Paolo Dei Tos, Antonio Russo, Giuseppe Badalamenti, Carla Rabitti, Giuseppe Tonini, Bruno Vincenzi, Paolo G. Casali, Vincenzi, B, Perrone, G, Santini, D, Grosso, F, Silletta, M, Frezza, A, Rossi, S, Russo, A, Rabitti, C, Gebbia, N, Badalamenti, G, Casali, P, Muda, AO, Dei tos, AP, Tonini, G, and Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, Tonini G.
- Subjects
Leiomyosarcoma ,Pathology ,medicine.medical_specialty ,Physiology ,soft tissue tumor ,Settore MED/06 - Oncologia Medica ,Clinical Biochemistry ,Down-Regulation ,Liposarcoma ,Promyelocytic Leukemia Protein ,Pleomorphic Liposarcoma ,PML, sarcomas ,Promyelocytic leukemia protein ,medicine ,Humans ,sarcomas ,neoplasms ,Myxoid liposarcoma ,PML ,biology ,business.industry ,Soft tissue sarcoma ,Tumor Suppressor Proteins ,Nuclear Proteins ,Sarcoma ,Cell Biology ,Anatomy ,medicine.disease ,Immunohistochemistry ,Synovial sarcoma ,body regions ,biology.protein ,business ,Transcription Factors - Abstract
To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantly down-regulated in synovial sarcoma and in myofibroblastic sarcoma specimens. Also in angiosarcoma samples a significative difference in PML expression in comparison with normal specimens has been detected. Interestingly PML protein detection showed a different pattern of expression in the three liposarcoma histology types compared with corresponding nontumoral tissues. In particular PML protein resulted significantly down-regulated in myxoid liposarcoma and in dedifferentiated liposarcoma. On the contrary no statistically significant difference was observed in pleomorphic liposarcoma compared to normal tissue specimens. Further investigations are needed to confirm these data and to assess the possible value of PML expression as a prognostic factor in these extremely aggressive diseases.
- Published
- 2010
10. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients
- Author
-
Fotios Loupakis, Alfredo Falcone, Sergio Rizzo, Gaia Schiavon, Carla Rabitti, Pierfilippo Crucitti, Daniele Santini, Annamaria Ruzzo, Giuseppe Tonini, Giuseppe Perrone, Bruno Vincenzi, Anna Maria Frezza, Francesco Graziano, Antonio Russo, Andrea Onetti Muda, Alice Zoccoli, Sara Galluzzo, Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis, F, Schiavon, G, Frezza, AM, Ruzzo, AM, Rizzo, S, Crucitti, P, Galluzzo, S, Zoccoli, A, Rabitti, C, Muda, AO, Russo, A, Falcone, A, and Tonini, G
- Subjects
Oncology ,Male ,Organoplatinum Compounds ,Oxaloacetates ,Physiology ,Colorectal cancer ,Settore MED/06 - Oncologia Medica ,viruses ,Clinical Biochemistry ,Cell ,Leucovorin ,Promyelocytic Leukemia Protein ,medicine.disease_cause ,Deoxycytidine ,Antineoplastic Combined Chemotherapy Protocols ,biology ,virus diseases ,Nuclear Proteins ,Middle Aged ,Oxaliplatin ,Survival Rate ,medicine.anatomical_structure ,Immunohistochemistry ,oxaliplatin/fluoropyrimidine ,Female ,Fluorouracil ,Colorectal Neoplasms ,medicine.drug ,Adult ,medicine.medical_specialty ,Antimetabolites, Antineoplastic ,PML ,colorectal cancer ,Antineoplastic Agents ,Promyelocytic leukemia protein ,Predictive Value of Tests ,Internal medicine ,medicine ,Humans ,Capecitabine ,Aged ,Retrospective Studies ,business.industry ,Tumor Suppressor Proteins ,Retrospective cohort study ,Cell Biology ,medicine.disease ,Apoptosis ,Drug Resistance, Neoplasm ,biology.protein ,Carcinogenesis ,business ,Transcription Factors - Abstract
PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P
- Published
- 2012
11. Pre-COVID-19-pandemic RSV epidemiology and clinical burden in pediatric primary care in Italy: a comparative analysis across two regions for the 2019/2020 season.
- Author
-
Pandolfi E, Loconsole D, Chironna M, van Summeren J, Paget J, Raponi M, Russo L, Campagna I, Croci I, Concato C, Perno CF, Tozzi AE, Linardos G, Bartolucci V, Ciampini S, Muda AO, De Angelis L, Ciofi Degli Atti ML, and Rizzo C
- Subjects
- Child, Humans, Infant, Child, Preschool, Hospitalization, Seasons, Prospective Studies, Pandemics, Italy epidemiology, Primary Health Care, Respiratory Syncytial Virus, Human genetics, COVID-19 epidemiology, Respiratory Syncytial Virus Infections epidemiology, Respiratory Tract Infections epidemiology
- Abstract
Background: Respiratory syncytial virus (RSV) infection in children under 5 years have a significant clinical burden, also in primary care settings. This study investigates the epidemiology and burden of RSV in Italian children during the 2019/20 pre-pandemic winter season., Methods: A prospective cohort study was conducted in two Italian regions. Children with Acute Respiratory Infection (ARI) visiting pediatricians were eligible. Nasopharyngeal swabs were collected and analyzed via multiplex PCR for RSV detection. A follow-up questionnaire after 14 days assessed disease burden, encompassing healthcare utilization and illness duration. Statistical analyses, including regression models, explored associations between variables such as RSV subtype and regional variations., Results: Of 293 children with ARI, 41% (119) tested positive for RSV. Median illness duration for RSV-positive cases was 7 days; 6% required hospitalization (median stay: 7 days). Medication was prescribed to 95% (110/116) of RSV cases, with 31% (34/116) receiving antibiotics. RSV subtype B and regional factors predicted increased healthcare utilization. Children with shortness of breath experienced a 36% longer illness duration., Conclusions: This study highlights a significant clinical burden and healthcare utilization associated with RSV in pre-pandemic Italian primary care settings. Identified predictors, including RSV subtype and symptomatology, indicate the need for targeted interventions and resource allocation strategies. RSV epidemiology can guide public health strategies for the implementation of preventive measures., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
12. Histologic and Clinical Factors Associated with Kidney Outcomes in IgA Vasculitis Nephritis.
- Author
-
Barbour SJ, Coppo R, Er L, Pillebout E, Russo ML, Alpers CE, Fogo AB, Ferrario F, Jennette JC, Roberts ISD, Cook HT, Ding J, Su B, Zhong X, Fervenza FC, Zand L, Peruzzi L, Lucchetti L, Katafuchi R, Shima Y, Yoshikawa N, Ichikawa D, Suzuki Y, Murer L, Wyatt RJ, Park C, Nelson RD, Narus JH, Wenderfer S, Geetha D, Daugas E, Monteiro RC, Nakatani S, Mastrangelo A, Nuutinen M, Koskela M, Weber LT, Hackl A, Pohl M, Pecoraro C, Tsuboi N, Yokoo T, Takafumi I, Fujimoto S, Conti G, Santoro D, Materassi M, Zhang H, Shi S, Liu ZH, Tesar V, Maixnerova D, Avila-Casado C, Bajema I, Barreca A, Becker JU, Comstock JM, Cornea V, Eldin K, Hernandez LH, Hou J, Joh K, Lin M, Messias N, Muda AO, Pagni F, Diomedi-Camassei F, Tokola H, D'Armiento M, Seidl M, Rosenberg A, Sannier A, Soares MF, Wang S, Zeng C, and Haas M
- Subjects
- Adult, Child, Humans, Male, Adolescent, Glomerular Filtration Rate, Kidney pathology, Proteinuria etiology, Biopsy, Retrospective Studies, Glomerulonephritis, IGA complications, Glomerulonephritis, IGA drug therapy, Glomerulonephritis, IGA pathology, IgA Vasculitis complications, IgA Vasculitis drug therapy, IgA Vasculitis pathology, Nephritis complications
- Abstract
Background: Nephritis is a common manifestation of IgA vasculitis and is morphologically indistinguishable from IgA nephropathy. While MEST-C scores are predictive of kidney outcomes in IgA nephropathy, their value in IgA vasculitis nephritis has not been investigated in large multiethnic cohorts., Methods: Biopsies from 262 children and 99 adults with IgA vasculitis nephritis ( N =361) from 23 centers in North America, Europe, and Asia were independently scored by three pathologists. MEST-C scores were assessed for correlation with eGFR/proteinuria at biopsy. Because most patients ( N =309, 86%) received immunosuppression, risk factors for outcomes were evaluated in this group using latent class mixed models to identify classes of eGFR trajectories over a median follow-up of 2.7 years (interquartile range, 1.2-5.1). Clinical and histologic parameters associated with each class were determined using logistic regression., Results: M, E, T, and C scores were correlated with either eGFR or proteinuria at biopsy. Two classes were identified by latent class mixed model, one with initial improvement in eGFR followed by a late decline (class 1, N =91) and another with stable eGFR (class 2, N =218). Class 1 was associated with a higher risk of an established kidney outcome (time to ≥30% decline in eGFR or kidney failure; hazard ratio, 5.84; 95% confidence interval, 2.37 to 14.4). Among MEST-C scores, only E1 was associated with class 1 by multivariable analysis. Other factors associated with class 1 were age 18 years and younger, male sex, lower eGFR at biopsy, and extrarenal noncutaneous disease. Fibrous crescents without active changes were associated with class 2., Conclusions: Kidney outcome in patients with biopsied IgA vasculitis nephritis treated with immunosuppression was determined by clinical risk factors and endocapillary hypercellularity (E1) and fibrous crescents, which are features that are not part of the International Study of Diseases of Children classification., (Copyright © 2024 by the American Society of Nephrology.)
- Published
- 2024
- Full Text
- View/download PDF
13. Accuracy of Pancreatic Stone Protein for diagnosis of sepsis in children admitted to pediatric intensive care or high-dependency care: a pilot study.
- Author
-
Bottari G, Caruso M, Paionni E, De Luca M, Romani L, Pisani M, Grandin A, Gargiullo L, Zampini G, Gagliardi C, Fegatelli DA, Vestri A, Lancella L, Porzio O, Muda AO, Villani A, Atti MCD, Raponi M, and Cecchetti C
- Subjects
- Humans, Child, Pilot Projects, Biomarkers, Calcitonin, Procalcitonin, ROC Curve, Critical Care, Prognosis, Lithostathine, Sepsis diagnosis
- Abstract
Background: Pancreatic Stone Protein (PSP) is one of the most promising diagnostic and prognostic markers. The aim of the study was to assess the accuracy of PSP, compared to C-Reactive Protein (CRP), and Procalcitonin (PCT) for sepsis diagnosis in pediatric patients. Furthermore, we explored the correlation of PSP levels with sepsis severity and organ failure measured with PELOD-2 score., Methods: Forty pediatric patients were enrolled following admission to pediatric intensive care, high dependency care or pediatric ward. PSP blood levels were measured in Emergency Department (nanofluidic point-of-care immunoassay; abioSCOPE, Abionic SA, Switzerland) on day 1, 2, 3, 5 and 7 from the onset of the clinical signs and symptoms of sepsis or SIRS. Inclusion criteria were: 1) patient age (1 month to 18 years old), 2) signs and symptoms of SIRS, irrespective of association with organ dysfunction. Exclusion criteria were: 1) hemato-oncological diseases and/or immunodeficiencies, 2) pancreatic diseases., Results: Septic patients showed higher PSP levels than those with non-infectious systemic inflammation. The optimal cut-off in diagnosis of sepsis for PSP at day 1 was 167 ng/ml resulted in a sensitivity of 59% (95% IC 36%-79%) and a specificity of 83% (95% IC 58%-96%) with an AUC of 0.636 for PSP in comparison to AUC of 0.722 for PCT and 0.503 for C-RP. ROC analysis for outcome (survival versus no survival) has showed AUC 0.814 for PSP; AUC 0.814 for PCT; AUC of 0.657 for C-RP., Conclusions: PSP could distinguish sepsis from non-infectious systemic inflammation; however, our results need to be confirmed in larger pediatric population., (© 2023. Società Italiana di Pediatria.)
- Published
- 2023
- Full Text
- View/download PDF
14. Changes in Total Homocysteine and Glutathione Levels After Laparoscopic Sleeve Gastrectomy in Children with Metabolic-Associated Fatty Liver Disease.
- Author
-
Pastore A, Panera N, Mosca A, Caccamo R, Camanni D, Crudele A, De Stefanis C, Alterio A, Di Giovamberardino G, De Vito R, Francalanci P, Battaglia S, Muda AO, De Peppo F, and Alisi A
- Subjects
- Child, Gastrectomy adverse effects, Glutathione, Homocysteine, Humans, Treatment Outcome, Laparoscopy adverse effects, Non-alcoholic Fatty Liver Disease complications, Obesity, Morbid surgery, Pediatric Obesity complications, Pediatric Obesity surgery
- Abstract
Purpose: Paediatric obesity is a well-known risk factor for metabolic-associated fatty liver disease (MAFLD). The aim of this study was to evaluate the effects of laparoscopic sleeve gastrectomy (LSG) on the levels of total homocysteine (tHcy) and total glutathione (tGSH) plasma levels in children with MAFLD., Material and Methods: Twenty-four children with severe obesity who underwent LSG were included in the study. The metabolic parameters, systemic inflammatory markers, one-carbon metabolism products, ultrasound and histological improvement were evaluated at baseline (T0M) and after 12 months from LSG (T12M)., Results: The patients exhibited a significant amelioration of several metabolic parameters at T12M. A significant reduction of steatosis was observed at ultrasound (from 72.7% of moderate-severe grade to 0% severe steatosis), accompanied by a statistically significant improvement of ballooning, portal and lobular inflammation and fibrosis. A statistically significant decrease of tumour necrosis factor circulating levels was also observed (T0M median = 290.3, IQR = 281.0-317.0 pg/mL; T12M median = 260.4, IQR = 240.0-279.0 pg/mL; p < 0.0001). After 12 months from LSG, a significant increase of mean plasma levels of tHcy(T0M mean = 15.7 ± 4.1 μmol/L; T12M mean = 21.1 ± 9.3 μmol/L; p = 0.0146) was also observed. The increase of tHcy showed no causal link with the improvement of MAFLD-related inflammatory, metabolic and histological pattern., Conclusion: LSG in children with obesity induces an improvement of MAFLD-related metabolic derangement and liver damage, but also a mild hyperhomocysteinemia that should be avoided to prevent cardiovascular risk., (© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
15. Cross-correlation of virome-bacteriome-host-metabolome to study respiratory health.
- Author
-
Iorio A, Biazzo M, Gardini S, Muda AO, Perno CF, Dallapiccola B, and Putignani L
- Subjects
- Metabolome, Virome, Gastrointestinal Microbiome, Microbiota, Viruses genetics
- Abstract
A comprehensive understanding of the microbiome-host relationship in respiratory diseases can be elucidated by exploring the landscape of virome-bacteriome-host metabolome data through unsupervised 'multi-omics' approaches. Here, we describe how the composition and function of airway and gut virome and bacteriome may contribute to pathogen establishment and propagation in airway districts and how the virome-bacteriome communities may react to respiratory diseases. A new systems medicine approach, including the characterization of respiratory and gut microbiome, may be crucial to demonstrate the likelihood and odds of respiratory disease pathophysiology, opening new avenues to the discovery of a chain of causation for key bacteria and viruses in disease severity., (Copyright © 2021 Elsevier Ltd. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
16. Sars-Cov2 Not Detected in a Pediatric Population With Acute Respiratory Infection in Primary Care in Central and Southern Italy From November 2019 to Early March 2020.
- Author
-
Rizzo C, Loconsole D, Pandolfi E, Ciofi Degli Atti ML, van Summeren J, Paget J, Russo L, Campagna I, Croci I, Gesualdo F, Concato C, Linardos G, Bartolucci V, Ciampini S, Muda AO, Raponi M, and Chironna M
- Abstract
Background: In December 2019, a novel coronavirus named SARS-CoV-2 started circulating in China and this led to a major epidemic in Northern Italy between February and May 2020. Young children (aged <5 years) seem to be less affected by this coronavirus disease (COVID-19) compared to adults, although there is very little information on the circulation of this new virus among children in Italy. We retrospectively tested nasopharyngeal swabs for SARS-CoV-2 in samples collected in young children between November, 2019 and March, 2020 in the context of the RSV ComNet study. Methods: Two networks of primary care pediatricians in Lazio (Central Italy) and Puglia (Southern Italy) collected nasopharyngeal swabs from children, aged <5 years, presenting with symptoms for an acute respiratory infection (ARI). The RSV ComNet study is a multicenter study implemented to estimate the burden of RSV in young children (aged <5 years) in the community. Swabs were sent to a central reference laboratory and tested for 14 respiratory viruses through RT-PCR. All collected samples were retrospectively tested for SARS-CoV-2 using RT-PCR (Istituto Superiore di Sanità protocol). Results: A total of 293 children with ARI were identified in the two participating networks. The highest number of cases were recruited in weeks 51/2019 and 3/2020. The majority of patients (57%) came from the Lazio region. All of the 293 samples tested negative for SARS-Cov2. Rhinovirus was the most frequently detected virus (44%), followed by RSV (41%) and influenza viruses (14%). Conclusions: Our study shows that in Lazio (a region of intermediate SARS-COV-2 incidence) and Puglia (a region of low incidence), the SARS-Cov2 virus did not circulate in a sample of ARI pediatric cases consulting primary care pediatricians between November 2019 and March 2020., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Rizzo, Loconsole, Pandolfi, Ciofi Degli Atti, van Summeren, Paget, Russo, Campagna, Croci, Gesualdo, Concato, Linardos, Bartolucci, Ciampini, Muda, Raponi and Chironna.)
- Published
- 2021
- Full Text
- View/download PDF
17. Facing SARS-CoV-2 Pandemic at a COVID-19 Regional Children's Hospital in Italy.
- Author
-
Ciofi Degli Atti ML, Campana A, Muda AO, Concato C, Ravà L, Ricotta L, Reale A, Barbieri M, D'Argenio P, Lancella L, Villani A, and Raponi M
- Subjects
- Adolescent, Ambulatory Care, Betacoronavirus isolation & purification, COVID-19, Child, Child, Preschool, Coronavirus Infections therapy, Coronavirus Infections virology, Emergency Service, Hospital organization & administration, Emergency Service, Hospital statistics & numerical data, Female, Hospitalization statistics & numerical data, Hospitals, Pediatric organization & administration, Hospitals, Pediatric statistics & numerical data, Humans, Infant, Italy epidemiology, Male, Pandemics, Pneumonia, Viral therapy, Pneumonia, Viral virology, SARS-CoV-2, Tertiary Care Centers organization & administration, Tertiary Care Centers statistics & numerical data, Civil Defense, Coronavirus Infections epidemiology, Pneumonia, Viral epidemiology
- Abstract
Background: In Italy, the response to coronavirus disease 2019 (COVID-19) pandemic upgraded from social distancing on February 23, 2020, to national lockdown on March 11, 2020. We described how the pandemic affected a tertiary care children hospital with a dedicated COVID-19 regional center., Methods: We analyzed the characteristics of emergency department (ED) visits, urgent hospitalizations and severe acute respiratory syndrome (SARS)-COV-2 reverse transcription-polymerase chain reaction testing, and COVID-19 patients across 3 response phases: before the first Italian case, before national lockdown and during lockdown., Results: ED visits decreased from a daily mean of 239.1 before the first COVID-19 Italian case, to 79.6 during lockdown; urgent hospitalizations decreased from 30.6 to 21.2. As of April 20, 2020, 1970 persons were tested for SARS-CoV-2 reverse transcription-polymerase chain reaction and 2.6% were positive. Positive rates were 1.2% in the ED, 21.1% in the COVID center and 0.5% in other wards. The median age of COVID-19 patients (N = 33) was 6.7 years, 27% had coexisting conditions and 79% were related to family clusters., Conclusions: The pandemic strongly impacted on the use of hospital services, with a 67% reduction in ED visits and a 31% reduction in urgent hospitalizations. Separating the flows of suspected patients from all other patients, and centralization of suspected and confirmed cases in the COVID center enabled to control the risk of nosocomial SARS-CoV-2 transmission. Delay in hospital use for urgent care must be avoided, and clear communication on infection prevention and control must be provided to families. Further studies are needed to assess how the reduction in hospital use affected children healthcare needs during the pandemic.
- Published
- 2020
- Full Text
- View/download PDF
18. Human equilibrative nucleoside transporter 1 gene expression is associated with gemcitabine efficacy in advanced leiomyosarcoma and angiosarcoma.
- Author
-
Vincenzi B, Stacchiotti S, Collini P, Pantano F, Rabitti C, Perrone G, Iuliani M, Baldi A, Badalamenti G, Sanfilippo R, Santini D, Muda AO, Gronchi A, Casali P, Dei Tos AP, and Tonini G
- Subjects
- Adult, Aged, Aged, 80 and over, Deoxycytidine therapeutic use, Disease-Free Survival, Female, Gene Expression, Hemangiosarcoma drug therapy, Humans, Kaplan-Meier Estimate, Leiomyosarcoma drug therapy, Male, Middle Aged, Retrospective Studies, Survival Rate, Gemcitabine, Antimetabolites, Antineoplastic therapeutic use, Deoxycytidine analogs & derivatives, Equilibrative Nucleoside Transporter 1 genetics, Hemangiosarcoma genetics, Leiomyosarcoma genetics
- Abstract
Background: The expression of human equilibrative nucleoside transporter 1 (hENT1), the major gemcitabine transporter into cells, has been thoroughly investigated as a predictive marker of response to gemcitabine in pancreatic cancer and biliary tract cancers. Since gemcitabine is widely used in the treatment of leiomyosarcoma and angiosarcoma, we investigated the correlation between hENT1 expression and gemcitabine efficacy in these sarcoma subtypes., Methods: We retrospectively identified 71 patients affected by advanced angiosarcoma (26) or leiomyosarcoma (45) treated within five Italian referral centres for sarcoma; among them, 49 patients (15 angiosarcoma, 34 leiomyosarcoma) were treated with gemcitabine. All tumour samples were analysed for hENT1 expression by real-time PCR. Median 2
-ΔCt value was used as the cutoff to dichotomise patients into 'high' expression and 'low' expression groups. Kaplan-Meier analysis was performed to estimate progression-free survival (PFS) and overall survival (OS)., Results: We found a significant association between high hENT1 expression levels and favourable outcome in terms of PFS and OS compared to cases with low hENT1 expression in leiomyosarcoma treated with gemcitabine (PFS: 6.8 vs 3.2 months, P=0.004; OS: 14.9 vs 8.5 months, P=0.007). In addition, hENT1 overexpression correlated with a significant improvement in PFS (9.3 vs 4.5 months; P=0.02) and OS (20.6 vs 10.8 months; P=0.001) in angiosarcoma patients treated with gemcitabine., Conclusions: Our study suggests that higher hENT1 expression are associated to gemcitabine efficacy both in patients with advanced leiomyosarcoma and angiosarcoma.- Published
- 2017
- Full Text
- View/download PDF
19. Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
- Author
-
Martinelli E, Cardone C, Troiani T, Normanno N, Pisconti S, Sforza V, Bordonaro AR, Rachiglio AM, Lambiase M, Latiano TP, Modoni G, Cordio S, Giuliani F, Biglietto M, Montesarchio V, Barone C, Tonini G, Cinieri S, Febbraro A, Rizzi D, De Vita F, Orditura M, Colucci G, Maiello E, Ciardiello F, Iaffaioli V, Nasti G, Nappi A, Botti G, Tatangelo F, Chicchinelli N, Montrone M, Sebastio A, Guarino T, Simone G, Graziano P, Chiarazzo C, Maggio G, Longhitano L, Manusia M, Cartenì G, Nappi O, Micheli P, Leo L, Rossi S, Cassano A, Tommaselli E, Giordano G, Sponziello F, Marino A, Rinaldi A, Romito S, Muda AO, Lorusso V, Leo S, Barni S, Grimaldi G, and Aieta M
- Abstract
Background: In the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin (FOLFOX) with or without cetuximab until progression. Limited data are available on the efficacy and safety of anti-epidermal growth factor receptor (anti-EGFR) agents on elderly patients with mCRC. In the current study we evaluated the efficacy and safety of FOLFIRI plus cetuximab in age-defined subgroups., Methods: A post-hoc analysis was performed in CAPRI trial patients; outcomes (progression-free survival (PFS), overall response rate (ORR), safety) were analysed by age-groups and stratified according to molecular characterisation. 3 age cut-offs were used to define the elderly population (≥65; ≥70 and ≥75 years)., Results: 340 patients with mCRC were treated in first line with FOLFIRI plus cetuximab. Among those, 154 patients were >65 years, 86 >70 years and 35 >75 years. Next-generation sequencing (NGS) was performed in 182 patients. Among them, 87 patients were >65 years, 46 >70 and 17 >75. 104 of 182 patients were wild type (WT) for KRAS, NRAS, BRAF, PIK3CA genes. In the quadruple WT group, 51 patients were ≥65 years; 29 were ≥70; 9 were ≥75. Median PFS was similar within the age-subgroups in the intention-to-treat population, NGS cohort and quadruple WT patients, respectively. Likewise, ORR was not significantly different among age-subgroups in the 3 populations. Safety profile was acceptable and similarly reported among all age-groups, with the exception of grade ≥3 diarrhoea (55% vs 25%, p=0.04) and neutropaenia (75% vs 37%, p=0.03) in patients ≥75 years and grade ≥3 fatigue (31% vs 20%, p=0.01) in patients <75 years., Conclusions: Tolerability of cetuximab plus FOLFIRI was acceptable in elderly patients. Similar ORR and PFS were observed according to age-groups. No differences in adverse events were reported among the defined subgroups with the exception of higher incidence of grade ≥3 diarrhoea and neutropaenia in patients ≥75 years and grade ≥3 fatigue in patients <75 years., Trial Registration Number: 2009-014041-81., Competing Interests: Competing interests: None declared.
- Published
- 2017
- Full Text
- View/download PDF
20. Efficacy of oral corticosteroids therapy in anti-glutamic acid decarboxylase antibodies cerebellar ataxia.
- Author
-
di Biase L, Assenza G, Iorio R, Melgari JM, Salomone G, Marano M, Muda AO, and Di Lazzaro V
- Subjects
- Administration, Oral, Cerebellar Ataxia blood, Cerebellar Ataxia diagnostic imaging, Gastric Mucosa metabolism, Humans, Magnetic Resonance Imaging, Middle Aged, Adrenal Cortex Hormones administration & dosage, Autoantibodies blood, Cerebellar Ataxia drug therapy, Glutamate Decarboxylase immunology
- Published
- 2016
- Full Text
- View/download PDF
21. Microscopic Residual Tumor After Pancreaticoduodenectomy: Is Standardization of Pathological Examination Worthwhile?
- Author
-
Borzomati D, Perrone G, Nappo G, Valeri S, Amato M, Petitti T, Muda AO, and Coppola R
- Subjects
- Aged, Ampulla of Vater pathology, Cohort Studies, Female, Humans, Male, Middle Aged, Neoplasm Recurrence, Local, Pathology, Clinical methods, Survival Analysis, Time Factors, Ampulla of Vater surgery, Carcinoma, Pancreatic Ductal surgery, Cholangiocarcinoma surgery, Neoplasm, Residual pathology, Pancreatic Neoplasms surgery, Pancreaticoduodenectomy methods
- Abstract
Objectives: R1 resection rate after pancreaticoduodenectomy (PD) for cancer is highly variable. The aim of this study was to verify if a standardized histopathological work-up of the specimen affects the rate of R1 resection after PD for cancer., Methods: Two groups of specimens were managed with (standardized method [SM] group) or without (non-standardized method [NSM] group) a SM of histopathological work-up. Each group included 50 cases of PD for periampullary cancer. Differences in terms of R1 resection rate between the 2 groups were evaluated. Correlation between R1 status and local recurrence was also evaluated., Results: The cohort of 100 patients consisted of 66 pancreatic ductal adenocarcinoma, 15 cholangiocarcinoma, and 19 ampullary cancer. The R1 resection rate resulted statistically higher in the SM group (66% vs 10%). Local recurrence was more frequently related to R1 resection in the SM group (34.3% of cases) than in NSM group (20% of cases)., Conclusions: The use of the SM of pathological evaluation of the specimen after PD for cancer determines a significant increase of R1 resection. This remarkable difference seems to be due to the different definition of minimum clearance. The SM seems to better discriminate patients in terms of risk of local recurrence.
- Published
- 2016
- Full Text
- View/download PDF
22. VEGF, BMP-7, Matrigel(TM), hyaluronic acid, in vitro cultured chondrocytes and trephination for healing of the avascular portion of the meniscus. An experimental study in sheep.
- Author
-
Forriol F, Longo UG, Duart J, Ripalda P, Vaquero J, Loppini M, Romeo G, Campi S, Khan WS, Muda AO, and Denaro V
- Subjects
- Animals, Cells, Cultured, Chondrocytes drug effects, Disease Models, Animal, Drug Combinations, Immunohistochemistry, Menisci, Tibial pathology, Regeneration drug effects, Sheep, Trephining, Bone Morphogenetic Protein 7 pharmacology, Chondrocytes transplantation, Collagen pharmacology, Hyaluronic Acid pharmacology, Laminin pharmacology, Menisci, Tibial drug effects, Proteoglycans pharmacology, Vascular Endothelial Growth Factor A pharmacology, Wound Healing drug effects
- Abstract
Objective: To evaluate the effects of VEGF, BMP-7, Matrigel(TM), hyaluronic acid, in vitro cultured chondrocytes and trephination to promote and enhance the healing process of avascular meniscal tears in an animal model., Methods: A longitudinal tear was produced in the inner avascular part of the meniscus of 24 sheeps. Each tear was treated with trephination technique and suture. The animals were divided into 6 groups to receive a different treatment: control (I); VEGF, BMP-7, Matrigel(TM), hyaluronic acid, in vitro cultured chondrocytes. At 8 weeks from surgery, meniscal samples were explanted and analyzed by histology, immunohistochemistry, and histomorphometry., Results: At the histological examination, Group IV and VI showed a partial closure of the meniscal lesion, whereas Group I, II, III, and V did not show any evidence of healing. In the group IV, the healed tissue represented the 22.95% of the lesion area. In the group VI, the healed tissue represented the 43.75% of the lesion area., Conclusions: Autologous chondrocytes and BMP-7 associated with trephination and suture techniques enhanced healing process of meniscal tears in the avascular inner third of the meniscus in ovine model.
- Published
- 2015
- Full Text
- View/download PDF
23. A challenging alfa-fetoprotein in a cirrhotic patient.
- Author
-
Gallo P, Gentilucci UV, Taffon C, Galati G, De Vincentis A, Muda AO, and Picardi A
- Subjects
- Adenocarcinoma secondary, Humans, Liver Cirrhosis etiology, Liver Cirrhosis pathology, Male, Middle Aged, Stomach Neoplasms secondary, Adenocarcinoma blood, Liver Cirrhosis blood, Liver Neoplasms blood, Liver Neoplasms pathology, Stomach Neoplasms blood, alpha-Fetoproteins metabolism
- Abstract
A 57-year-old Italian man was admitted to our Hospital for investigation of a progressively raising alfa-fetoprotein (AFP) on the background of chronic hepatitis B infection. At abdominal imaging,liver morphology was suspected for advanced fibrosis but without any focal lesion. Clinical and ultrasonographic examinations were negative for testicular masses. When the patient was screened for gastroesophageal varices, upper intestinal endoscopy did not show signs of portal hypertension, while it revealed a gastric lesion which was histologically characterized as hepatoid adenocarcinoma of the stomach (HAS), with strong immunohistochemical positivity for AFP. The patient underwent subtotal gastrectomy and AFP fell within the normal range. This is a very rare case in which AFP-producing gastric cancer (AFPPGC), in the form of HAS, presented in a patient with chronic liver disease. Physicians should be particularly aware of AFPPGC when following patients with liver disorders due to the common use of AFP in this setting.
- Published
- 2014
24. The role of macrophages polarization in predicting prognosis of radically resected gastric cancer patients.
- Author
-
Pantano F, Berti P, Guida FM, Perrone G, Vincenzi B, Amato MM, Righi D, Dell'aquila E, Graziano F, Catalano V, Caricato M, Rizzo S, Muda AO, Russo A, Tonini G, and Santini D
- Subjects
- Cell Polarity, Female, Gastrectomy, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Prognosis, Retrospective Studies, Stomach Neoplasms diagnosis, Stomach Neoplasms immunology, Stomach Neoplasms surgery, Treatment Outcome, Macrophages physiology, Stomach Neoplasms mortality
- Abstract
Tumour-associated Macrophages (TAM) present two different polarizations: classical (M1) characterized by immunostimulation activity and tumour suppression; alternative (M2) characterized by tumour promotion and immune suppression. In this retrospective study, we evaluated the correlation between the two forms of TAM with survival time in radically resected gastric cancer patients. A total of 52 chemo- and radio-naive patients were included. Two slides were prepared for each patient and double-stained for CD68/NOS2 (M1) or CD68/CD163 (M2) and five representative high-power fields per slide were evaluated for TAM count. The median value of the two macrophage populations density and the median value of M1/M2 ratio were used as cut-off. Twenty-seven patients with M1 density above-the-median had a significantly higher survival compared to those below the median. Twenty-six patients with M1/M2 ratio above the median showed median OS of 27.2 months compared to 15.5 months of the patients below the median. No association between M2 macrophage density and patient's outcome was found. In multivariate analysis, M1/M2 was a positive independent predictor of survival. The M1 macrophage density and M1/M2 ratio, as confirmed in multivariate analysis, are factors that can help in predicting patients survival time after radical surgery for gastric cancer., (© 2013 The Authors. Journal of Cellular and Molecular Medicine Published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.)
- Published
- 2013
- Full Text
- View/download PDF
25. AKT2 is essential to maintain podocyte viability and function during chronic kidney disease.
- Author
-
Canaud G, Bienaimé F, Viau A, Treins C, Baron W, Nguyen C, Burtin M, Berissi S, Giannakakis K, Muda AO, Zschiedrich S, Huber TB, Friedlander G, Legendre C, Pontoglio M, Pende M, and Terzi F
- Subjects
- Animals, Disease Progression, Humans, Kidney Failure, Chronic pathology, Mechanistic Target of Rapamycin Complex 2, Mice, Mice, Knockout, Multiprotein Complexes physiology, Nephrons metabolism, Nephrons physiopathology, Proto-Oncogene Proteins c-akt genetics, TOR Serine-Threonine Kinases physiology, Kidney Failure, Chronic metabolism, Podocytes cytology, Proto-Oncogene Proteins c-akt physiology
- Abstract
In chronic kidney disease (CKD), loss of functional nephrons results in metabolic and mechanical stress in the remaining ones, resulting in further nephron loss. Here we show that Akt2 activation has an essential role in podocyte protection after nephron reduction. Glomerulosclerosis and albuminuria were substantially worsened in Akt2(-/-) but not in Akt1(-/-) mice as compared to wild-type mice. Specific deletion of Akt2 or its regulator Rictor in podocytes revealed that Akt2 has an intrinsic function in podocytes. Mechanistically, Akt2 triggers a compensatory program that involves mouse double minute 2 homolog (Mdm2), glycogen synthase kinase 3 (Gsk3) and Rac1. The defective activation of this pathway after nephron reduction leads to apoptosis and foot process effacement of the podocytes. We further show that AKT2 activation by mammalian target of rapamycin complex 2 (mTORC2) is also required for podocyte survival in human CKD. More notably, we elucidate the events underlying the adverse renal effect of sirolimus and provide a criterion for the rational use of this drug. Thus, our results disclose a new function of Akt2 and identify a potential therapeutic target for preserving glomerular function in CKD.
- Published
- 2013
- Full Text
- View/download PDF
26. Prognostic value of glomerular collagen IV immunofluorescence studies in male patients with X-linked Alport syndrome.
- Author
-
Massella L, Gangemi C, Giannakakis K, Crisafi A, Faraggiana T, Fallerini C, Renieri A, Muda AO, and Emma F
- Subjects
- Adolescent, Adult, Age Factors, Biomarkers analysis, Biopsy, Child, Child, Preschool, Disease Progression, Glomerular Basement Membrane pathology, Glomerular Basement Membrane physiopathology, Glomerular Filtration Rate, Humans, Infant, Kaplan-Meier Estimate, Male, Microscopy, Fluorescence, Nephritis, Hereditary genetics, Nephritis, Hereditary pathology, Nephritis, Hereditary physiopathology, Predictive Value of Tests, Prognosis, Proteinuria genetics, Proteinuria metabolism, Retrospective Studies, Time Factors, Young Adult, Autoantigens analysis, Collagen Type IV analysis, Fluorescent Antibody Technique, Glomerular Basement Membrane chemistry, Nephritis, Hereditary metabolism
- Abstract
Background and Objectives: X-linked Alport syndrome (X-AS) is caused by mutations of the COL4A5 gene, which encodes for the collagen IV α5 chain (α5[COLIV]), resulting in structural and functional abnormalities of the glomerular basement membrane (GBM) and leading to CKD. The aim of the present study was to evaluate the prognostic value of residual collagen IV chain expression in the GBM of patients with X-AS., Design, Setting, Participants, & Measurements: The medical records of 22 patients with X-AS from 21 unrelated families collected between 1987 and 2009 were reviewed (median age at last follow-up, 19.9 years; range, 5.4-35.1 years); GBM expression of α1, α3, and α5(COLIV) chains was assessed by immunofluorescence microscopy., Results: GBM distribution of the α5(COLIV) chain was diffuse in 1 and segmental or absent in 21 of the 22 patients; the expression of the α3(COLIV) chain was diffuse in 5 of 22 patients and segmental or absent in 17 of 22 patients. Patients with diffuse staining for the α3(COLIV) chain presented with proteinuria significantly later (median age, 16.9 versus 6.1 years; P=0.02) and reached an estimated GFR < 90 ml/min per 1.73 m(2) at an older age (median age, 27.0 versus 14.9 years; P=0.01) compared with patients with segmental or absent staining. Two thirds of patients with abnormal α3(COLIV) expression by immunofluorescence studies had null or truncating COL4A5 mutations, as opposed to none of the 4 tested patients with diffuse α3(COLIV) chain glomerular distribution., Conclusions: These results indicate that maintained expression of the α3(COLIV) chain is an early positive prognostic marker in patients with X-linked Alport symdrome.
- Published
- 2013
- Full Text
- View/download PDF
27. Dicer and Drosha expression and response to Bevacizumab-based therapy in advanced colorectal cancer patients.
- Author
-
Vincenzi B, Zoccoli A, Schiavon G, Iuliani M, Pantano F, Dell'aquila E, Ratta R, Muda AO, Perrone G, Brunelli C, Correale P, Riva E, Russo A, Loupakis F, Falcone A, Santini D, and Tonini G
- Subjects
- Adult, Aged, Aged, 80 and over, Angiogenesis Inhibitors therapeutic use, Bevacizumab, Colorectal Neoplasms pathology, DEAD-box RNA Helicases metabolism, Female, Gene Expression Profiling, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Intestinal Mucosa metabolism, Intestinal Mucosa pathology, Kaplan-Meier Estimate, Male, Middle Aged, Multivariate Analysis, Oligonucleotide Array Sequence Analysis, Prognosis, Reverse Transcriptase Polymerase Chain Reaction, Ribonuclease III metabolism, Treatment Outcome, Young Adult, Antibodies, Monoclonal, Humanized therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, DEAD-box RNA Helicases genetics, Ribonuclease III genetics
- Abstract
Purpose: The miRNA-regulating enzymes Dicer and Drosha exhibit aberrant expression in several cancer types. Dicer and Drosha play a crucial role during the angiogenetic process in vitro and, for Dicer, in vivo. We aimed to investigate the potential role of Dicer and Drosha in predicting response to Bevacizumab-based therapy in advanced colorectal cancer (CRC) patients., Methods: Dicer and Drosha mRNA levels were analysed in formalin-fixed paraffin-embedded specimens from patients affected by advanced CRC treated with or without Bevacizumab-containing regimens (n=116 and n=50, respectively) and from patients with diverticulosis as control group (n=20). The experimental data were obtained using qRT-PCR, analysed comparing Dicer and Drosha expression levels in tumour samples versus normal mucosa and then compared to clinical outcome., Results: The tumour samples from Bevacizumab-treated patients showed a significantly higher Drosha expression (P<.001) versus normal mucosa, while Dicer levels did not differ. Intriguingly, we found that low Dicer levels predicted a longer progression-free survival (PFS) (P<.0001) and overall survival (OS) (P=.009). In addition, low Dicer levels were associated with better response to Bevacizumab-based treatments versus high Dicer levels (1.7% complete responses and 53.4% partial responses versus 0% and 32.7%, respectively; P=.0067). Multivariate analysis identified three independent predictors of improved OS: high performance status (PS) (relative risk (RR) 1.45; P=.011), lower organs involvement (RR 0.79; P=.034) and low Dicer expression (RR 0.71; P=.008). Conversely, Drosha levels were not associated with prognosis and outcome associated with treatment. In non-Bevacizumab-treated patients, Dicer and Drosha expression did not correlate with outcome., Conclusion: These findings suggest that low Dicer mRNA levels seem to be independent predictors of favourable outcome and response in patients affected by advanced CRCs treated with Bevacizumab-based therapy., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
28. In situ electrostimulation drives a regenerative shift in the zone of infarcted myocardium.
- Author
-
Spadaccio C, Rainer A, De Marco F, Lusini M, Gallo P, Sedati P, Muda AO, De Porcellinis S, Gregorj C, Avvisati G, Trombetta M, Chello M, Covino E, Bull DA, Patel AN, and Genovese JA
- Subjects
- Animals, Atrial Natriuretic Factor genetics, Atrial Natriuretic Factor metabolism, Cell Movement, Cell- and Tissue-Based Therapy, Electrodes, Implanted, Endothelium, Vascular cytology, Female, Myocardial Infarction metabolism, Myocardial Infarction therapy, Myocytes, Cardiac cytology, Myocytes, Cardiac physiology, Neovascularization, Physiologic, Rats, Rats, Wistar, Regeneration, Stem Cells cytology, Stem Cells metabolism, Tomography, X-Ray Computed, Vascular Endothelial Growth Factor A metabolism, Ventricular Function, Left physiology, Electric Stimulation, Myocardial Infarction physiopathology
- Abstract
Electrostimulation represents a well-known trophic factor for different tissues. In vitro electrostimulation of non-stem and stem cells induces myogenic predifferentiation and may be a powerful tool to generate cells with the capacity to respond to local areas of injury. We evaluated the effects of in vivo electrostimulation on infarcted myocardium using a miniaturized multiparameter implantable stimulator in rats. Parameters of electrostimulation were organized to avoid a direct driving or pacing of native heart rhythm. Electrical stimuli were delivered for 14 days across the scar site. In situ electrostimulation used as a cell-free, cytokine-free stimulation system, improved myocardial function, and increased angiogenesis through endothelial progenitor cell migration and production of vascular endothelial growth factor (VEGF). In situ electrostimulation represents a novel means to stimulate repair of the heart and other organs, as well as to precondition tissues for treatment with cell-based therapies.
- Published
- 2013
- Full Text
- View/download PDF
29. Aberrant promoter methylation of beta-1,4 galactosyltransferase 1 as potential cancer-specific biomarker of colorectal tumors.
- Author
-
Poeta ML, Massi E, Parrella P, Pellegrini P, De Robertis M, Copetti M, Rabitti C, Perrone G, Muda AO, Molinari F, Zanellato E, Crippa S, Caputo D, Caricato M, Frattini M, Coppola R, and Fazio VM
- Subjects
- Aged, DNA Methylation, Female, Galactosyltransferases metabolism, Gene Expression Regulation, Neoplastic, Humans, Male, Microsatellite Instability, Middle Aged, Phenotype, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins B-raf metabolism, Proto-Oncogene Proteins p21(ras), RNA, Messenger metabolism, ras Proteins genetics, ras Proteins metabolism, Biomarkers, Tumor genetics, Colorectal Neoplasms genetics, Galactosyltransferases genetics, Promoter Regions, Genetic
- Abstract
Epigenetic alterations, such as CpG islands methylation and histone modifications, are recognized key characteristics of cancer. Glycogenes are a group of genes which epigenetic status was found to be changed in several tumors. In this study, we determined promoter methylation status of the glycogene beta-1,4-galactosyltransferase 1 (B4GALT1) in colorectal cancer patients. Methylation status of B4GALT1 was assessed in 130 colorectal adenocarcinomas, 13 adenomas, and in paired normal tissue using quantitative methylation specific PCR (QMSP). B4GALT1 mRNA expression was evaluated in methylated/unmethylated tumor and normal specimens. We also investigated microsatellite stability and microsatellite instability status and KRAS/BRAF mutations. Discriminatory power of QMSP was assessed by receiving operating curve (ROC) analysis on a training set of 24 colorectal cancers and paired mucosa. The area under the ROC curve (AUC) was 0.737 (95% confidence interval [CI]:0.591-0.881, P = 0.005) with an optimal cutoff value of 2.07 yielding a 54% sensitivity (95% CI: 35.1%-72.1%) and a specificity of 91.7% (95% CI: 74.1%-97.7%). These results were confirmed in an independent validation set where B4GALT1 methylation was detected in 52/106 patients. An inverse correlation was observed between methylation and B4GALT1 mRNA expression levels (r = -0.482, P = 0.037). Significant differences in methylation levels and frequencies was demonstrated in invasive lesions as compared with normal mucosa (P = 0.0001) and in carcinoma samples as compared with adenoma (P = 0.009). B4GALT1 methylation is a frequent and specific event in colorectal cancer and correlates with downregulation of mRNA expression. These results suggest that the glycogene B4GALT1 represent a valuable candidate biomarker of invasive phenotype of colorectal cancer., (Copyright © 2012 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
30. Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus.
- Author
-
Barchetta I, Carotti S, Labbadia G, Gentilucci UV, Muda AO, Angelico F, Silecchia G, Leonetti F, Fraioli A, Picardi A, Morini S, and Cavallo MG
- Subjects
- Adiponectin blood, Adult, Aged, Blood Glucose metabolism, Calcifediol blood, Cross-Sectional Studies, Cytochrome P450 Family 2, Fatty Liver blood, Fatty Liver pathology, Female, Hepatitis C, Chronic blood, Hepatitis C, Chronic pathology, Hepatocytes metabolism, Humans, Insulin blood, Male, Middle Aged, Non-alcoholic Fatty Liver Disease, Severity of Illness Index, Statistics, Nonparametric, Cholestanetriol 26-Monooxygenase metabolism, Fatty Liver metabolism, Hepatitis C, Chronic metabolism, Receptors, Calcitriol metabolism
- Abstract
Unlabelled: Evidence suggests an association between low serum 25-hydroxy-vitamin D(3) [25(OH)D(3) ] levels and the presence and prognosis of liver disease. Vitamin D receptor (VDR) has been widely detected in the liver, but its expression in the course of liver disease has never been investigated. We evaluated the hepatic expression of VDR along with that of vitamin D 25-hydroxylases in patients with nonalcoholic steatohepatitis (NASH) or chronic hepatitis C (CHC) and its relationship with hepatic histological features and serum 25(OH)D(3) levels. We evaluated 61 patients (25 NASH and 36 CHC) who had undergone liver biopsy for clinical purposes and 20 subjects without liver disease. Serum 25(OH)D(3) was measured via colorimetric assay. Expression of VDR, CYP2R1, and CYP27A1 was evaluated via immunohistochemistry in hepatocytes, cholangiocytes, and liver inflammatory cells. Parenchymal and inflammatory cells from liver biopsies of patients with NASH and CHC expressed VDR, CYP2R1, and CYP27A1. In NASH patients, VDR expression on cholangiocytes was inversely correlated with steatosis severity (P < 0.02), lobular inflammation (P < 0.01), and nonalcoholic fatty liver disease score (P < 0.03). Moreover, expression of CYP2R1 in hepatocytes correlated strongly with VDR positivity on liver inflammatory cells. In CHC subjects, fibrosis stage was associated with low hepatic CYP27A1 expression, whereas portal inflammation was significantly higher in patients with VDR-negative inflammatory cells (P < 0.009) and low VDR expression in hepatocytes (P < 0.03)., Conclusion: VDR is widely expressed in the liver and inflammatory cells of chronic liver disease patients and its expression is negatively associated with the severity of liver histology in both NASH and CHC patients. These data suggest that vitamin D/VDR system may play a role in the progression of metabolic and viral chronic liver damage. (HEPATOLOGY 2012;56:2180-2187)., (Copyright © 2012 American Association for the Study of Liver Diseases.)
- Published
- 2012
- Full Text
- View/download PDF
31. PML as a potential predictive factor of oxaliplatin/fluoropyrimidine-based first line chemotherapy efficacy in colorectal cancer patients.
- Author
-
Vincenzi B, Santini D, Perrone G, Graziano F, Loupakis F, Schiavon G, Frezza AM, Ruzzo AM, Rizzo S, Crucitti P, Galluzzo S, Zoccoli A, Rabitti C, Muda AO, Russo A, Falcone A, and Tonini G
- Subjects
- Adult, Aged, Antimetabolites, Antineoplastic therapeutic use, Capecitabine, Colorectal Neoplasms secondary, Deoxycytidine analogs & derivatives, Deoxycytidine therapeutic use, Drug Resistance, Neoplasm physiology, Female, Fluorouracil analogs & derivatives, Humans, Leucovorin therapeutic use, Male, Middle Aged, Organoplatinum Compounds therapeutic use, Oxaliplatin, Oxaloacetates, Predictive Value of Tests, Promyelocytic Leukemia Protein, Retrospective Studies, Survival Rate, Antineoplastic Agents therapeutic use, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms metabolism, Fluorouracil therapeutic use, Nuclear Proteins metabolism, Transcription Factors metabolism, Tumor Suppressor Proteins metabolism
- Abstract
PML regulates a wide range of pathways involved in tumorigenesis, such as apoptosis, which is also one of the main mechanisms through which oxaliplatin and fluoropyrimidine exert their antineoplastic activity. The present study aims to investigate PML expression as a predictive factor of oxaliplatin/fluoropyrimidine therapy efficacy. Seventy-four metastatic colorectal cancer patients who received oxaliplatin/floropyrimidine-based first line therapy have been included in this retrospective study. PML expression was assessed by immunohistochemistry. PML down-regulation was detected in 39 (52.7%) patients (14 complete and 25 partial PML loss). RR was significantly lower (25.6%) in patients with PML down-regulation than in patients with preserved PML expression (60%) (P = 0.006). Median TTP was 5.5 months when PML was down-regulated versus 11.9 months in case of preserved PML expression (P < 0.0001). A statistical significant difference was also detected in OS (15.6 and 24.5 months, respectively, P = 0.003). The impact of PML down-regulation on TTP and OS was statistically significant also in a multivariate model. This study represents the first evidence of a possible correlation between PML protein expression and outcome of metastatic colorectal cancer patients treated with oxaliplatin/fluoropyrimidine-based first line therapy., (Copyright © 2011 Wiley Periodicals, Inc.)
- Published
- 2012
- Full Text
- View/download PDF
32. In situ identification of CD44+/CD24- cancer cells in primary human breast carcinomas.
- Author
-
Perrone G, Gaeta LM, Zagami M, Nasorri F, Coppola R, Borzomati D, Bartolozzi F, Altomare V, Trodella L, Tonini G, Santini D, Cavani A, and Muda AO
- Subjects
- Adult, Aged, Aged, 80 and over, Biomarkers, Tumor metabolism, Breast Neoplasms mortality, Breast Neoplasms pathology, Carcinoma mortality, Carcinoma pathology, Female, Humans, Immunophenotyping, Mammary Glands, Human metabolism, Middle Aged, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Staging, Breast Neoplasms metabolism, CD24 Antigen metabolism, Carcinoma metabolism, Hyaluronan Receptors metabolism
- Abstract
Breast cancer cells with the CD44+/CD24- phenotype have been reported to be tumourigenic due to their enhanced capacity for cancer development and their self-renewal potential. The identification of human tumourigenic breast cancer cells in surgical samples has recently received increased attention due to the implications for prognosis and treatment, although limitations exist in the interpretation of these studies. To better identify the CD44+/CD24- cells in routine surgical specimens, 56 primary breast carcinoma cases were analysed by immunofluorescence and confocal microscopy, and the results were compared using flow cytometry analysis to correlate the amount and distribution of the CD44+/CD24- population with clinicopathological features. Using these methods, we showed that the breast carcinoma cells displayed four distinct sub-populations based on the expression pattern of CD44 and CD24. The CD44+/CD24- cells were found in 91% of breast tumours and constituted an average of 6.12% (range, 0.11%-21.23%) of the tumour. A strong correlation was found between the percentage of CD44+/CD24- cells in primary tumours and distant metastasis development (p = 0.0001); in addition, there was an inverse significant association with ER and PGR status (p = 0.002 and p = 0.001, respectively). No relationship was evident with tumour size (T) and regional lymph node (N) status, differentiation grade, proliferative index or HER2 status. In a multivariate analysis, the percentage of CD44+/CD24- cancer cells was an independent factor related to metastasis development (p = 0.004). Our results indicate that confocal analysis of fluorescence-labelled breast cancer samples obtained at surgery is a reliable method to identify the CD44+/CD24- tumourigenic cell population, allowing for the stratification of breast cancer patients into two groups with substantially different relapse rates on the basis of CD44+/CD24- cell percentage.
- Published
- 2012
- Full Text
- View/download PDF
33. High RAD51 mRNA expression characterize estrogen receptor-positive/progesteron receptor-negative breast cancer and is associated with patient's outcome.
- Author
-
Barbano R, Copetti M, Perrone G, Pazienza V, Muscarella LA, Balsamo T, Storlazzi CT, Ripoli M, Rinaldi M, Valori VM, Latiano TP, Maiello E, Stanziale P, Carella M, Mangia A, Pellegrini F, Bisceglia M, Muda AO, Altomare V, Murgo R, Fazio VM, and Parrella P
- Subjects
- Biomarkers, Tumor analysis, Breast Neoplasms metabolism, DNA Breaks, Double-Stranded, Disease Progression, Estrogen Receptor alpha, Female, Humans, Neoplasms, Hormone-Dependent, Prognosis, RNA, Messenger metabolism, Receptors, Progesterone metabolism, Treatment Outcome, Rad51 Recombinase genetics
- Abstract
Mutations in DNA double-strand breaks (DSB) repair genes are involved in the pathogenesis of hereditary mammary tumors, it is, however, still unclear whether defects in this pathway may play a role in sporadic breast cancer. In this study, we initially determined mRNA expression of 15 DSB related genes by reverse transcription quantitative polymerase chain reaction in paired normal tissue and cancer specimen from 20 breast cancer cases to classify them into homogeneous clusters. G22P1/ku70, ATR and RAD51 genes were differentially expressed in the three branches recognized by clustering analysis. In particular, a breast cancer subgroup characterized by high RAD51 mRNA levels and estrogen receptor (ER)-positive/progesteron receptor (PR)-negative phenotype was identified. This result was confirmed by the analysis of G22P1/ku70, ATR and RAD51 mRNA levels on paired normal and tumor specimens from an extended breast cancer cohort (n = 75). RAD51 mRNA levels were inversely associated with PR status (p = 0.02) and the highest levels were, indeed, detected in ER-positive/PR-negative tumors (p = 0.03). RAD51 immunostaining of a tissue microarray confirmed the inverse relationship between high RAD51 expression and negative PR status (p = 0.002), as well as, the association with ER-positive/PR-negative phenotype (p = 0.003). Interestingly, the analysis of microarray expression data from 295 breast cancers indicate that RAD51 increased mRNA expression is associated with higher risk of tumor relapse, distant metastases and worst overall survival (p = 0.015, p = 0.009 and p = 0.013 respectively). Our results suggest that RAD51 expression determination could contribute to a better molecular classification of mammary tumors and may represent a novel tool for evaluating postoperative adjuvant therapy for breast cancer patients., (Copyright © 2010 UICC.)
- Published
- 2011
- Full Text
- View/download PDF
34. Sytemic strongyloidiasis and primary aspergillosis of digestive tract in a patient with T-cell acute lymphoblastic leukemia.
- Author
-
Marchesi F, Lepanto D, Annibali O, Cerchiara E, Tirindelli MC, Bianchi A, Sedati P, Muda AO, and Avvisati G
- Subjects
- Aged, Aspergillus isolation & purification, Female, Humans, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma microbiology, Prognosis, Aspergillosis etiology, Gastrointestinal Tract microbiology, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma complications, Strongyloidiasis etiology
- Published
- 2011
- Full Text
- View/download PDF
35. Receptor activator of NF-kB (RANK) expression in primary tumors associates with bone metastasis occurrence in breast cancer patients.
- Author
-
Santini D, Schiavon G, Vincenzi B, Gaeta L, Pantano F, Russo A, Ortega C, Porta C, Galluzzo S, Armento G, La Verde N, Caroti C, Treilleux I, Ruggiero A, Perrone G, Addeo R, Clezardin P, Muda AO, and Tonini G
- Subjects
- Aged, Breast Neoplasms pathology, Female, Humans, Immunohistochemistry methods, Ligands, Middle Aged, Neoplasm Metastasis, Oligonucleotide Array Sequence Analysis, Osteoprotegerin biosynthesis, RANK Ligand biosynthesis, RNA, Messenger metabolism, Bone Neoplasms secondary, Breast Neoplasms metabolism, Gene Expression Regulation, Neoplastic, Receptor Activator of Nuclear Factor-kappa B biosynthesis
- Abstract
Background: Receptor activator of NFkB (RANK), its ligand (RANKL) and the decoy receptor of RANKL (osteoprotegerin, OPG) play a pivotal role in bone remodeling by regulating osteoclasts formation and activity. RANKL stimulates migration of RANK-expressing tumor cells in vitro, conversely inhibited by OPG., Materials and Methods: We examined mRNA expression levels of RANKL/RANK/OPG in a publicly available microarray dataset of 295 primary breast cancer patients. We next analyzed RANK expression by immunohistochemistry in an independent series of 93 primary breast cancer specimens and investigated a possible association with clinicopathological parameters, bone recurrence and survival., Results: Microarray analysis showed that lower RANK and high OPG mRNA levels correlate with longer overall survival (P = 0.0078 and 0.0335, respectively) and disease-free survival (P = 0.059 and 0.0402, respectively). Immunohistochemical analysis of RANK showed a positive correlation with the development of bone metastases (P = 0.023) and a shorter skeletal disease-free survival (SDFS, P = 0.037). Specifically, univariate analysis of survival showed that "RANK-negative" and "RANK-positive" patients had a SDFS of 105.7 months (95% CI: 73.9-124.4) and 58.9 months (95% CI: 34.7-68.5), respectively. RANK protein expression was also associated with accelerated bone metastasis formation in a multivariate analysis (P = 0.029)., Conclusions: This is the first demonstration of the role of RANK expression in primary tumors as a predictive marker of bone metastasis occurrence and SDFS in a large population of breast cancer patients.
- Published
- 2011
- Full Text
- View/download PDF
36. Should oncologists be aware in their clinical practice of KRAS molecular analysis?
- Author
-
Santini D, Galluzzo S, Gaeta L, Zoccoli A, Riva E, Ruzzo A, Vincenzi B, Graziano F, Loupakis F, Falcone A, Muda AO, and Tonini G
- Subjects
- Attitude of Health Personnel, Awareness, Codon, Colorectal Neoplasms drug therapy, Colorectal Neoplasms secondary, ErbB Receptors antagonists & inhibitors, Health Knowledge, Attitudes, Practice, Humans, Molecular Targeted Therapy, Patient Selection, Polymerase Chain Reaction, Predictive Value of Tests, Proto-Oncogene Proteins p21(ras), Retrospective Studies, Antineoplastic Agents therapeutic use, Colorectal Neoplasms genetics, DNA Mutational Analysis, Genetic Testing methods, Mutation, Precision Medicine, Protein Kinase Inhibitors therapeutic use, Proto-Oncogene Proteins genetics, ras Proteins genetics
- Published
- 2011
- Full Text
- View/download PDF
37. PML down-regulation in soft tissue sarcomas.
- Author
-
Vincenzi B, Perrone G, Santini D, Grosso F, Silletta M, Frezza A, Rossi S, Russo A, Rabitti C, Gebbia N, Badalamenti G, Casali P, Muda AO, Dei Tos AP, and Tonini G
- Subjects
- Humans, Immunohistochemistry, Promyelocytic Leukemia Protein, Sarcoma therapy, Down-Regulation, Nuclear Proteins metabolism, Sarcoma metabolism, Sarcoma pathology, Transcription Factors metabolism, Tumor Suppressor Proteins metabolism
- Abstract
To date, little is known concerning the promyelocytic leukemia gene (PML) status in tumors of different origin, and its expression has never been evaluated in soft tissue sarcoma. The aim of the present study is focused on the identification of differences in terms of PML protein expression between different types of soft tissue sarcoma and the corresponding normal surrounding tissue. PML protein expression has been assessed by immunohistochemistry in six different histologic types of soft tissue sarcoma (synovial sarcoma, myofibroblastic sarcoma, angiosarcoma, liposarcoma, pleomorphic sarcoma, and leiomyosarcoma) and in the corresponding normal surrounding tissue. PML resulted significantly down-regulated in synovial sarcoma and in myofibroblastic sarcoma specimens. Also in angiosarcoma samples a significative difference in PML expression in comparison with normal specimens has been detected. Interestingly PML protein detection showed a different pattern of expression in the three liposarcoma histology types compared with corresponding nontumoral tissues. In particular PML protein resulted significantly down-regulated in myxoid liposarcoma and in dedifferentiated liposarcoma. On the contrary no statistically significant difference was observed in pleomorphic liposarcoma compared to normal tissue specimens. Further investigations are needed to confirm these data and to assess the possible value of PML expression as a prognostic factor in these extremely aggressive diseases., ((c) 2010 Wiley-Liss, Inc.)
- Published
- 2010
- Full Text
- View/download PDF
38. Cyclosporine A treatment in patients with Alport syndrome: a single-center experience.
- Author
-
Massella L, Muda AO, Legato A, Di Zazzo G, Giannakakis K, and Emma F
- Subjects
- Adolescent, Adult, Child, Female, Humans, Kidney Failure, Chronic etiology, Male, Nephritis, Hereditary complications, Nephritis, Hereditary diagnosis, Proteinuria etiology, Proteinuria pathology, Treatment Outcome, Young Adult, Cyclosporine therapeutic use, Immunosuppressive Agents therapeutic use, Nephritis, Hereditary drug therapy, Proteinuria drug therapy
- Abstract
Limited and discordant data are available on cyclosporine A (CsA) treatment for proteinuria in Alport syndrome (AS). To address this lack of consistent data, we have studied 15 AS patients (14 males; mean age 15.3 +/- 6.0 years) treated with CsA. Patient selection criteria included a urinary protein/creatinine ratio > or =1 mg/mg and a creatinine clearance >40 ml/min/1.73 m(2). CsA treatment was started at an initial dose of 5 mg/kg/day and subsequently adjusted to reach target C2 levels of 500 ng/ml. Renal function, proteinuria, and blood pressure were monitored. Blood pressure was treated to avoid the administration of angiotensin converting enzyme or angiotensin receptor blockers for the first 2 years of therapy. The average follow-up was 3.5 years. Five patients had chronic renal failure at the beginning of treatment, of whom three and one reached end-stage renal failure within 1 and 3 years, respectively. In the remaining 11 patients, the glomerular filtration rate declined by 11 +/- 6% within 6 months, but remained stable thereafter. Proteinuria decreased by 63 +/- 21% from baseline, but returned nearly to baseline after 2.5 years of follow-up. Based on these results, we suggest that CsA is effective in reducing proteinuria in patients with Alport syndrome but that this effect is temporary. Our data do not support the use of CsA therapy for proteinuric patients with AS, particularly if they have chronic renal failure.
- Published
- 2010
- Full Text
- View/download PDF
39. Prognostic role of human equilibrative transporter 1 (hENT1) in patients with resected gastric cancer.
- Author
-
Santini D, Vincenzi B, Fratto ME, Perrone G, Lai R, Catalano V, Cass C, Ruffini PA, Spoto C, Muretto P, Rizzo S, Muda AO, Mackey JR, Russo A, Tonini G, and Graziano F
- Subjects
- Adenocarcinoma mortality, Adult, Aged, Aged, 80 and over, Antineoplastic Agents metabolism, Antineoplastic Agents pharmacokinetics, Biomarkers, Tumor analysis, Cohort Studies, Disease Progression, Disease-Free Survival, Drug Resistance, Neoplasm physiology, Equilibrative Nucleoside Transporter 1 analysis, Female, Gastric Mucosa pathology, Gastric Mucosa physiopathology, Humans, Immunohistochemistry, Male, Middle Aged, Neoplasm Metastasis physiopathology, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local prevention & control, Predictive Value of Tests, Prognosis, Retrospective Studies, Stomach Neoplasms mortality, Survival Rate, Adenocarcinoma diagnosis, Adenocarcinoma metabolism, Biomarkers, Tumor metabolism, Equilibrative Nucleoside Transporter 1 metabolism, Gastric Mucosa metabolism, Stomach Neoplasms diagnosis, Stomach Neoplasms metabolism
- Abstract
Nucleoside transporter proteins are specialized proteins that mediate the transport of nucleosides and nucleoside analog drugs across the plasma membrane. The human equilibrative nucleoside transporter 1 (hENT1) is a member of these proteins and mediates cellular entry of gemcitabine, cytarabine, and fludarabine. The hENT1 expression has been demonstrated to be related with prognosis and activity of gemcitabine-based therapy in breast, ampullary, lung, and pancreatic cancer. We investigated the immunohistochemical expression of hENT in tumor samples from 111 patients with resected gastric adenocarcinoma, correlating these data with clinical parameters and disease outcomes. None of the patients received chemotherapy or radiation therapy before or after surgery as a part of an adjuvant or neoadjuvant program. On univariate survival analysis, the hENT1 expression was associated with overall survival (OS) and disease free survival (DFS). Specifically, those patients with overexpression of hENT1 showed a shorter OS (P = 0.021) and a shorter DFS (P = 0.033). Considering only the node positive patients, higher hENT levels were associated with significantly shorter median DFS (21.7 months; 95% CI 11.1-32.4) compared with patients with low expression of hENT1. The hENT1 expression was defined, in the lymph-node positive patients, as an independent prognostic factor (P = 0.019). Furthermore, considering only patients with diffuse or mixed tumors and lymph-node positive, the expression of hENT1 was strongly related with DFS and OS. Immunohistochemistry for the hENT1 protein carries prognostic information in patients with resected gastric cancer and holds promise as a predictive factor in chemotherapy decisions.
- Published
- 2010
- Full Text
- View/download PDF
40. Predictors of benefit in colorectal cancer treated with cetuximab: are we getting "Lost in TranslationAL"?
- Author
-
Cremolini C, Loupakis F, Ruzzo A, Perrone G, Rulli E, Vincenzi B, Tonini G, Graziano F, Muda AO, and Falcone A
- Subjects
- Antibodies, Monoclonal, Humanized, Cetuximab, Colorectal Neoplasms metabolism, ErbB Receptors antagonists & inhibitors, ErbB Receptors metabolism, Humans, Immunoenzyme Techniques, Prognosis, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins B-raf genetics, Proto-Oncogene Proteins p21(ras), Receptors, Androgen metabolism, Retrospective Studies, ras Proteins genetics, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents therapeutic use, Colorectal Neoplasms drug therapy, Colorectal Neoplasms genetics, Mutation genetics
- Published
- 2010
- Full Text
- View/download PDF
41. Identification of CANT1 mutations in Desbuquois dysplasia.
- Author
-
Huber C, Oulès B, Bertoli M, Chami M, Fradin M, Alanay Y, Al-Gazali LI, Ausems MG, Bitoun P, Cavalcanti DP, Krebs A, Le Merrer M, Mortier G, Shafeghati Y, Superti-Furga A, Robertson SP, Le Goff C, Muda AO, Paterlini-Bréchot P, Munnich A, and Cormier-Daire V
- Subjects
- 5' Untranslated Regions, Adolescent, Adult, Amino Acid Sequence, Amino Acid Substitution, Arginine metabolism, Bone Diseases, Developmental diagnostic imaging, Cells, Cultured, Child, Preschool, Chondrocytes metabolism, Chromosomes, Human, Pair 17, Codon, Nonsense, Consanguinity, Endoplasmic Reticulum, Rough ultrastructure, Exons, Fatal Outcome, Female, Fibroblasts ultrastructure, Homozygote, Humans, Infant, Infant, Newborn, Male, Molecular Sequence Data, Mutation, Missense, Nuclear Family, RNA, Messenger metabolism, Radiography, Bone Diseases, Developmental genetics, Calcium metabolism, Mutation, Nucleotidases genetics
- Abstract
Desbuquois dysplasia is a severe condition characterized by short stature, joint laxity, scoliosis, and advanced carpal ossification with a delta phalanx. Studying nine Desbuquois families, we identified seven distinct mutations in the Calcium-Activated Nucleotidase 1 gene (CANT1), which encodes a soluble UDP-preferring nucleotidase belonging to the apyrase family. Among the seven mutations, four were nonsense mutations (Del 5' UTR and exon 1, p.P245RfsX3, p.S303AfsX20, and p.W125X), and three were missense mutations (p.R300C, p.R300H, and p.P299L) responsible for the change of conserved amino acids located in the seventh nucleotidase conserved region (NRC). The arginine substitution at position 300 was identified in five out of nine families. The specific function of CANT1 is as yet unknown, but its substrates are involved in several major signaling functions, including Ca2+ release, through activation of pyrimidinergic signaling. Importantly, using RT-PCR analysis, we observed a specific expression in chondrocytes. We also found electron-dense material within distended rough endoplasmic reticulum in the fibroblasts of Desbuquois patients. Our findings demonstrate the specific involvement of a nucleotidase in the endochondral ossification process.
- Published
- 2009
- Full Text
- View/download PDF
42. Podocin inactivation in mature kidneys causes focal segmental glomerulosclerosis and nephrotic syndrome.
- Author
-
Mollet G, Ratelade J, Boyer O, Muda AO, Morisset L, Lavin TA, Kitzis D, Dallman MJ, Bugeon L, Hubner N, Gubler MC, Antignac C, and Esquivel EL
- Subjects
- Animals, Female, Gene Expression Profiling, Integrases physiology, Intracellular Signaling Peptides and Proteins genetics, Kidney Glomerulus metabolism, Kidney Tubules pathology, Male, Membrane Proteins genetics, Mice, Podocytes ultrastructure, Glomerulosclerosis, Focal Segmental etiology, Intracellular Signaling Peptides and Proteins physiology, Kidney metabolism, Membrane Proteins physiology, Nephrotic Syndrome etiology
- Abstract
Podocin is a critical component of the glomerular slit diaphragm, and genetic mutations lead to both familial and sporadic forms of steroid-resistant nephrotic syndrome. In mice, constitutive absence of podocin leads to rapidly progressive renal disease characterized by mesangiolysis and/or mesangial sclerosis and nephrotic syndrome. Using established Cre-loxP technology, we inactivated podocin in the adult mouse kidney in a podocyte-specific manner. Progressive loss of podocin in the glomerulus recapitulated albuminuria, hypercholesterolemia, hypertension, and renal failure seen in nephrotic syndrome in humans. Lesions of FSGS appeared after 4 wk, with subsequent development of diffuse glomerulosclerosis and tubulointerstitial damage. Interestingly, conditional inactivation of podocin at birth resulted in a gradient of glomerular lesions, including mesangial proliferation, demonstrating a developmental stage dependence of renal histologic patterns of injury. The development of significant albuminuria in this model occurred only after early and focal foot process effacement had progressed to diffuse involvement, with complete absence of podocin immunolabeling at the slit diaphragm. Finally, we identified novel potential mediators and perturbed molecular pathways, including cellular proliferation, in the course of progression of renal disease leading to glomerulosclerosis, using global gene expression profiling.
- Published
- 2009
- Full Text
- View/download PDF
43. Breast-like vulvar lesion with concurrent breast cancer: a case report and critical literature review.
- Author
-
Perrone G, Altomare V, Zagami M, Vulcano E, Muzii L, Battista C, Rabitti C, and Muda AO
- Subjects
- Aged, Diagnosis, Differential, Female, Humans, Breast Neoplasms pathology, Carcinoma, Ductal secondary, Vulvar Neoplasms secondary
- Abstract
In the current report, we describe an intriguing case of a breast-like cancer lesion located in the vulvar region in a woman lacking a remarkable past medical or family history of breast cancer but with concurrent breast cancer. Consequently, a differential diagnosis between a primary synchronous breast and vulvar cancer or a metastatic breast carcinoma to the vulva is a key point in terms of the clinical approach. In a review of the literature, 39 cases of breast-like cancer lesion have been described: 23 cases of primary infiltrating carcinoma of the vulva and 16 cases of vulvar metastases of breast carcinoma. To the best of our knowledge, this is the first report of a clinically synchronous vulvar metastasis from an invasive ductal carcinoma. The main diagnostic criteria for differential diagnosis between primary or metastatic breast-like vulvar carcinoma are also discussed.
- Published
- 2009
44. Differential vascular endothelial growth factor A protein expression between small hepatocellular carcinoma and cirrhosis correlates with serum vascular endothelial growth factor A and alpha-fetoprotein.
- Author
-
Corradini SG, Morini S, Liguori F, Carotti S, Muda AO, Burza MA, Siciliano M, Molinaro A, Cantafora A, Blotta I, Merli M, Berloco P, Rossi M, Attili AF, and Gaudio E
- Subjects
- Blotting, Western, Female, Humans, Immunohistochemistry, Italy, Liver Transplantation, Male, Middle Aged, Carcinoma, Hepatocellular blood, Gene Expression, Liver Cirrhosis blood, Vascular Endothelial Growth Factor A blood, alpha-Fetoproteins metabolism
- Abstract
Background/aims: Drugs with antivascular endothelial growth factor A (anti-VEGF-A) action are under clinical evaluation with encouraging results in advanced hepatocellular carcinoma (HCC). The relative VEGF-A protein expression in non-advanced HCC and in the cirrhotic non-tumoral tissue in the same patient, a variable that could be important for treatment efficacy, has been investigated with conflicting results, only using the cirrhotic tissue surrounding the neoplasm (CS)., Methods: We measured, for the first time, VEGF-A expression in non-advanced HCC and in the respective CS and cirrhotic tissue at a distance from the tumour (CD), in 24 patients who underwent liver transplantation., Results: VEGF-A protein was more expressed (P<0.05) in HCC than in CD, while no difference was found between HCC and CS. In HCC patients with a serum alpha-fetoprotein (AFP) higher than 20 ng/ml, VEGF-A protein expression in HCC was higher than in the corresponding CD in 83% of cases and AFP and serum VEGF-A corrected for the platelet count positively correlated with the differential VEGF-A protein expression between HCC and CD., Conclusion: Our data provide a rationale for clinical trials involving anti-VEGF-A treatments in patients with non-advanced HCC, and suggest that serum AFP and VEGF-A are variables to be taken into account in these studies.
- Published
- 2009
- Full Text
- View/download PDF
45. Caveolin-1 expression in human breast lobular cancer progression.
- Author
-
Perrone G, Altomare V, Zagami M, Morini S, Petitti T, Battista C, Muda AO, and Rabitti C
- Subjects
- Breast Neoplasms metabolism, Carcinoma in Situ metabolism, Carcinoma, Lobular metabolism, Disease Progression, Female, Humans, Immunohistochemistry, Biomarkers, Tumor analysis, Breast Neoplasms pathology, Carcinoma in Situ pathology, Carcinoma, Lobular pathology, Caveolin 1 biosynthesis
- Abstract
Caveolin-1 is the principal structural protein of caveolae, and caveolin-1 gene plays a role as a tumour suppressor gene in human mammary cancer-derived cells. However, limited data are available concerning caveolin-1 expression in human breast cancer tissue. We evaluated caveolin-1 expression in normal lobular epithelial cells and in the whole human lobular neoplasia spectrum disease, with the aim to examine differences of caveolin-1 expression in human lobular neoplasia progression. We selected 147 cases of pure lobular lesions, ie lobular intraepithelial neoplasia and invasive lobular carcinoma, from 112 patients. Presence of caveolin-1 was evaluated by immunohistochemistry. Among 81 lobular intraepithelial neoplasia lesions studied, 43% were associated with invasive lobular carcinoma, with positive correlation between lobular intraepithelial neoplasia grade and presence of invasive component (P=0.01). In total, 64% of lobular lesions were positive for caveolin-1 (81% lobular intraepithelial neoplasia and 42% invasive lobular carcinoma), and a significant difference in terms of caveolin-1 expression was present between lobular intraepithelial neoplasia and invasive lobular carcinoma (P=0.0001). Variations in caveolin-1 expression were evident among the different lobular intraepithelial neoplasia grades (91% grade 1, 68% grade 2, 35% grade 3); the difference was significant comparing lobular intraepithelial neoplasia grade 3 vs 1 (P=0.0001) and grade 3 vs 2 (P=0.007) but not grade 1 vs 2. Furthermore, significant differences were found between lobular intraepithelial neoplasia grades 1 and 2 vs invasive lobular carcinoma (P=0.0001), but not between lobular intraepithelial neoplasia grade 3 and invasive lobular carcinoma (P=0.196). In conclusion, variations of caveolin-1 expression may have an important role in the progression of human breast lobular cancer; in addition, they confirm the powerful clinical impact of the lobular intraepithelial neoplasia classification for lobular intraepithelial neoplasia, supporting the direct origin of invasive lobular carcinoma from clonal expansion of the lobular intraepithelial neoplasia lesions cells.
- Published
- 2009
- Full Text
- View/download PDF
46. Maternal environment interacts with modifier genes to influence progression of nephrotic syndrome.
- Author
-
Ratelade J, Lavin TA, Muda AO, Morisset L, Mollet G, Boyer O, Chen DS, Henger A, Kretzler M, Hubner N, Théry C, Gubler MC, Montagutelli X, Antignac C, and Esquivel EL
- Subjects
- Animals, Disease Progression, Female, Genomics, Kidney pathology, Male, Mice, Nephrotic Syndrome pathology, Phenotype, Environment, Intracellular Signaling Peptides and Proteins genetics, Membrane Proteins genetics, Nephrotic Syndrome genetics
- Abstract
Mutations in the NPHS2 gene, which encodes podocin, are responsible for some cases of sporadic and familial autosomal recessive steroid-resistant nephrotic syndrome. Inter- and intrafamilial variability in the progression of renal disease among patients bearing NPHS2 mutations suggests a potential role for modifier genes. Using a mouse model in which the podocin gene is constitutively inactivated, we sought to identify genetic determinants of the development and progression of renal disease as a result of the nephrotic syndrome. We report that the evolution of renal disease as a result of nephrotic syndrome in Nphs2-null mice depends on genetic background. Furthermore, the maternal environment significantly interacts with genetic determinants to modify survival and progression of renal disease. Quantitative trait locus mapping suggested that these genetic determinants may be encoded for by genes on the distal end of chromosome 3, which are linked to proteinuria, and on the distal end of chromosome 7, which are linked to a composite trait of urea, creatinine, and potassium. These loci demonstrate epistatic interactions with other chromosomal regions, highlighting the complex genetics of renal disease progression. In summary, constitutive inactivation of podocin models the complex interactions between maternal and genetically determined factors on the progression of renal disease as a result of nephrotic syndrome in mice.
- Published
- 2008
- Full Text
- View/download PDF
47. Glial fibrillary acidic protein as an early marker of hepatic stellate cell activation in chronic and posttransplant recurrent hepatitis C.
- Author
-
Carotti S, Morini S, Corradini SG, Burza MA, Molinaro A, Carpino G, Merli M, De Santis A, Muda AO, Rossi M, Attili AF, and Gaudio E
- Subjects
- Actins metabolism, Disease Progression, Fibrosis, Hepacivirus metabolism, Humans, Immunohistochemistry methods, Liver pathology, Microcirculation, Muscle, Smooth metabolism, Postoperative Period, Recurrence, Glial Fibrillary Acidic Protein metabolism, Hepatitis C diagnosis, Hepatitis C etiology, Liver cytology, Liver virology, Liver Transplantation adverse effects
- Abstract
Activated alpha-smooth muscle actin (alpha-SMA)-positive hepatic stellate cells (HSCs) are pericytes responsible for fibrosis in chronic liver injury. The glial fibrillary acidic protein (GFAP), commonly expressed by astrocytes in the central nervous system, is expressed in vivo in the liver in a subpopulation of quiescent stellate cells. In the rat, increased GFAP expression in the acute response to injury and down-regulation in the chronic response have been observed, whereas reports concerning GFAP expression in human liver are still conflicting. We investigated the utility of GFAP compared to alpha-SMA as an immunohistochemical marker of early activated HSCs in chronic and posttransplant recurrent hepatitis C and correlated GFAP expression with vascular remodeling and fibrosis progression. With immunohistochemistry and a semiquantitative scoring system, the expression of GFAP and alpha-SMA in HSCs and the microvessel density were analyzed in biopsies from normal livers obtained from cadaveric donors [donor liver (DL); n = 21] and from livers from posttransplant hepatitis C virus recurrent hepatitis (HCV-PTR) patients (n = 19), hepatitis C virus chronic hepatitis (HCV-CH) patients, (n = 12), and hepatitis C virus cirrhosis (HCV-C) patients (n = 16). The percentage of alpha-SMA-positive HSCs was significantly higher in the HCV-PTR, HCV-CH, and HCV-C groups compared to the DL group (P < 0.01). The percentage of GFAP-positive HSCs was significantly higher in the HCV-PTR group compared to the DL, HCV-C (P < 0.01), and HCV-CH (P < 0.05) groups and in the HCV-CH group compared to the DL group (P < 0.01), inversely correlating with the extent of fibrosis and microvessel density (P < 0.01). In the HCV-PTR group, the percentage of GFAP-positive HSCs correlated with fibrosis progression (P < 0.01). In conclusion, GFAP could represent a useful marker of early activation of HSCs in HCV-CH and seems to predict fibrosis progression in HCV-PTR.
- Published
- 2008
- Full Text
- View/download PDF
48. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy.
- Author
-
Giannakakis K, Feriozzi S, Perez M, Faraggiana T, and Muda AO
- Subjects
- Adolescent, Adult, Aged, Female, Glycosylation, Humans, Immune System, Immunoglobulin A metabolism, Male, Mesangial Cells metabolism, Microscopy, Confocal, Middle Aged, Glomerulonephritis, IGA diagnosis, Glomerulonephritis, IGA metabolism, Immunoglobulin A chemistry, Kidney Glomerulus metabolism
- Published
- 2007
- Full Text
- View/download PDF
49. Type VII collagen in Alport syndrome.
- Author
-
Giannakakis K, Massella L, Grassetti D, Dotta F, Perez M, and Muda AO
- Subjects
- Adolescent, Adult, Child, Child, Preschool, Collagen Type VII analysis, Female, Humans, Infant, Male, Middle Aged, Skin chemistry, Collagen Type VII metabolism, Nephritis, Hereditary metabolism
- Abstract
Background: Absence or segmental distribution of the alpha5(IV) collagen chain along the epidermal basement membrane (EBM) is diagnostic of X-linked Alport syndrome (X-AS), but the typical morphologic alterations usually observed along the glomerular basement membrane (GBM) are lacking. However, several differences in protein composition exist between GBM and EBM, and such differences could account for a different phenotype with the same genetic defect. Type VII collagen is one of the major collagenous components of the EBM; the purpose of this study was to investigate the modifications of protein synthesis and expression of type VII collagen in the skin of patients with X-AS., Methods: The distribution of type VII collagen has been studied in 15 skin biopsies (10 from X-AS patients and 5 controls) by means of electron microscopy, immunofluorescence and confocal microscopy; type VII collagen mRNA expression was also measured by RT-PCR on the same skin fragments., Results: Protein and mRNA amounts for type VII collagen were significantly higher in skin samples from X-AS patients than in controls (P < 0.001); highest values were in cases in which alpha5(IV) was completely absent., Conclusions: Our results indicate that lack of alpha5(IV) molecule significantly alters the assembly of extracellular matrix molecules other than alphax(IV) chains also at the EBM level. We suggest that the increased synthesis and deposition of type VII collagen is likely to balance the absence of stabilizing activity normally exerted by alpha5(IV).
- Published
- 2007
- Full Text
- View/download PDF
50. COQ2 nephropathy: a newly described inherited mitochondriopathy with primary renal involvement.
- Author
-
Diomedi-Camassei F, Di Giandomenico S, Santorelli FM, Caridi G, Piemonte F, Montini G, Ghiggeri GM, Murer L, Barisoni L, Pastore A, Muda AO, Valente ML, Bertini E, and Emma F
- Subjects
- Acute Kidney Injury pathology, Coenzymes deficiency, Electron Transport Chain Complex Proteins metabolism, Humans, Infant, Kidney metabolism, Male, Mitochondrial Diseases pathology, Muscle, Skeletal metabolism, Mutation, Missense, Nephrotic Syndrome pathology, Ubiquinone analogs & derivatives, Ubiquinone deficiency, Acute Kidney Injury genetics, Alkyl and Aryl Transferases genetics, Kidney pathology, Mitochondrial Diseases genetics, Nephrotic Syndrome genetics
- Abstract
Primary coenzyme Q(10) (CoQ(10)) deficiency includes a group of rare autosomal recessive disorders primarily characterized by neurological and muscular symptoms. Rarely, glomerular involvement has been reported. The COQ2 gene encodes the para-hydroxybenzoate-polyprenyl-transferase enzyme of the CoQ(10) synthesis pathway. We identified two patients with early-onset glomerular lesions that harbored mutations in the COQ2 gene. The first patient presented with steroid-resistant nephrotic syndrome at the age of 18 months as a result of collapsing glomerulopathy, with no extrarenal symptoms. The second patient presented at five days of life with oliguria, had severe extracapillary proliferation on renal biopsy, rapidly developed end-stage renal disease, and died at the age of 6 months after a course complicated by progressive epileptic encephalopathy. Ultrastructural examination of renal specimens from these cases, as well as from two previously reported patients, showed an increased number of dysmorphic mitochondria in glomerular cells. Biochemical analyses demonstrated decreased activities of respiratory chain complexes [II+III] and decreased CoQ(10) concentrations in skeletal muscle and renal cortex. In conclusion, we suggest that inherited COQ2 mutations cause a primary glomerular disease with renal lesions that vary in severity and are not necessarily associated with neurological signs. COQ2 nephropathy should be suspected when electron microscopy shows an increased number of abnormal mitochondria in podocytes and other glomerular cells.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.